Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.14, $0.32 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $47.35 million versus the consensus estimate of $47.28 million.

"We are excited with the year to date HETLIOZ sales performance, which demonstrates continued strength, and our HETLIOZ life cycle management program, which positions the product well for additional future growth," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. \"We are focused on our upcoming clinical milestones from the tradipitant gastroparesis study and the HETLIOZ Smith-Magenis Syndrome study."

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.